Literature DB >> 28293819

Characteristics features and factors influencing early death in Acute promyelocytic leukemia; Experience from United Arab Emirates (UAE).

Inaam Bashir Hassan1,2, Mariam R Al Zaabi3, Arif Alam4, Mohammed Jawad Hashim5, Martin S Tallman6, Jorgen Kristensen3.   

Abstract

Although acute promyelocytic leukemia (APL) is a curable hematologic malignancy, early death (ED) remains a significant cause of treatment failure especially in developing countries. In a retrospective data analysis of 67 adult APL patients diagnosed in United Arab Emirates we report an ED rate of 11.9% which is comparable to that reported from more developed countries. We identified the following parameters at presentation as significant predictor of increased ED: Age >40 years (P = 0.015), fever (P = 0.030), WBC count >20 × 109/L (P = 0.010), the breakpoints other than bcr1 (P = 0.043) and fibrinogen level <1.5 g/L (P = 0.025). Delay in ATRA administration beyond 24 h from admission and fibrinogen <150 mg/dL were also significant predictors of ED, but only among high-risk patients (P = 0.035 and P = 0.033, respectively). WBC count >10 × 109/L and expression of HLA-DR (P = 0.018) or CD2 (P = 0.017) were significant predictors for differentiation syndrome (DS) which was found to be a predictor of ED (P = 0.002). Reducing the APL related ED rate in centers with limited resources is feasible provided early initiation of ATRA administration and early correction of coagulopathy in high-risk patients in addition to prompt treatment of DS. To our knowledge this is the first report from the Arabian Gulf describing ED in APL.

Entities:  

Keywords:  Acute promyelocytic leukemia; Early death; United Arab Emirates

Mesh:

Year:  2017        PMID: 28293819     DOI: 10.1007/s12185-017-2211-7

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  53 in total

1.  Rapid diagnosis of acute promyelocytic leukemia (PML): applicability of flow cytometry and PML protein immunofluorescence.

Authors:  Matthew J Cullen; Stephen J Richards; Sheila J M O'Connor; Helen Dickinson; Carol Sharpe; David M Swirsky; Roger Owen
Journal:  Cancer Genet Cytogenet       Date:  2004-01-15

2.  Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks.

Authors:  Hongming Huang; Yan Qin; Ruirong Xu; Xuefeng You; Rong Teng; Li Yang; Mengqi Xu; Hong Liu
Journal:  Leuk Res       Date:  2012-04-23       Impact factor: 3.156

3.  Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.

Authors:  Yinjun Lou; Shanshan Suo; Hongyan Tong; Xingnong Ye; Yungui Wang; Zhimei Chen; Wenbin Qian; Haitao Meng; Wenyuan Mai; Jian Huang; Yin Tong; Jie Jin
Journal:  Leuk Res       Date:  2013-08-16       Impact factor: 3.156

4.  Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group.

Authors:  N Asou; K Adachi; J Tamura; A Kanamaru; S Kageyama; A Hiraoka; E Omoto; H Akiyama; K Tsubaki; K Saito; K Kuriyama; H Oh; K Kitano; S Miyawaki; K Takeyama; O Yamada; K Nishikawa; M Takahashi; S Matsuda; S Ohtake; H Suzushima; N Emi; R Ohno
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

5.  Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.

Authors:  S Lehmann; A Ravn; L Carlsson; P Antunovic; S Deneberg; L Möllgård; A Rangert Derolf; D Stockelberg; U Tidefelt; A Wahlin; L Wennström; M Höglund; G Juliusson
Journal:  Leukemia       Date:  2011-04-19       Impact factor: 11.528

6.  Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome.

Authors:  M S Tallman; J W Andersen; C A Schiffer; F R Appelbaum; J H Feusner; A Ogden; L Shepherd; J M Rowe; C François; R S Larson; P H Wiernik
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

Review 7.  Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

Authors:  Miguel A Sanz; David Grimwade; Martin S Tallman; Bob Lowenberg; Pierre Fenaux; Elihu H Estey; Tomoki Naoe; Eva Lengfelder; Thomas Büchner; Hartmut Döhner; Alan K Burnett; Francesco Lo-Coco
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

8.  International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation ≥ 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia.

Authors:  Mirjana Mitrovic; Nada Suvajdzic; Andrija Bogdanovic; Nada Kraguljac Kurtovic; Aleksandra Sretenovic; Ivo Elezovic; Dragica Tomin
Journal:  Med Oncol       Date:  2013-01-31       Impact factor: 3.064

9.  Delay in the administration of all-trans retinoic acid and its effects on early mortality in acute promyelocytic leukemia: final results of a multicentric study in the United States.

Authors:  Armin Rashidi; Meghan Riley; Teresa A Goldin; Farzaneh Sayedian; Michael G Bayerl; Nadine S Aguilera; Jeffrey A Vos; Ranjit K Goudar; Stephen I Fisher
Journal:  Leuk Res       Date:  2014-06-30       Impact factor: 3.156

Review 10.  Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid.

Authors:  L Vahdat; P Maslak; W H Miller; A Eardley; G Heller; D A Scheinberg; R P Warrell
Journal:  Blood       Date:  1994-12-01       Impact factor: 22.113

View more
  3 in total

1.  Comparative analysis of causes and predictors of early death in elderly and young patients with acute promyelocytic leukemia treated with arsenic trioxide.

Authors:  Bo Jin; Yingmei Zhang; Wenyi Hou; Fenglin Cao; Ming Lu; Huiyuan Yang; Xuanyu Tian; Yuan Wang; Jinxiao Hou; Jinyue Fu; Haitao Li; Jin Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-04       Impact factor: 4.553

2.  Analysis of risk factors for early death in patients with acute promyelocytic leukaemia treated with arsenic trioxide.

Authors:  Yuan Wang; Wenyi Hou; Haitao Li; Xuanyu Tian; Jinqiao Li; Tianming Hu; Deli Shi; Yingmei Zhang
Journal:  Ann Hematol       Date:  2022-02-16       Impact factor: 3.673

Review 3.  Effect of Therapeutically Related Drugs on Coagulation-Anticoagulation Balance in Acute Promyelocytic Leukemia.

Authors:  Mengyu Xiao; Pan Zhou; Kai Sun
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.